Ally Bridge Group’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.04M Buy
+16,493
New +$3.58M 3.57% 6
2025
Q2
Sell
-72,113
Closed -$8.41M 26
2025
Q1
$8.41M Buy
72,113
+5,452
+8% +$621K 7.58% 4
2024
Q4
$5.64M Buy
+66,661
New +$6.13M 4.84% 4
2024
Q1
Sell
-100,862
Closed -$8.03M 26
2023
Q4
$8.03M Sell
100,862
-9,738
-9% -$651K 4.78% 10
2023
Q3
$7.73M Buy
+110,600
New +$8.27M 9.07% 4

Other funds holding AXSM

Ally Bridge Group's AXSM Position: Q2 2026 in Review

Ally Bridge Group opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 16,493 shares worth $4.04M. The stake represents 3.57% of the portfolio and ranks #6 among its holdings. This is a return to the name: Ally Bridge Group previously reported a position in AXSM as recently as Q1 2025.

Ally Bridge Group first reported a position in AXSM in Q3 2023 and has held it in 5 quarters since. The position peaked at $8.41M in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Ally Bridge Group held 16,493 shares of Axsome Therapeutics worth $4.04M as of Q2 2026.
  • Axsome Therapeutics was a new Ally Bridge Group position in Q2 2026.
  • Axsome Therapeutics made up 3.57% of Ally Bridge Group's portfolio in Q2 2026, its #6 holding.
  • Ally Bridge Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 5 quarters since.
  • Ally Bridge Group's Axsome Therapeutics position peaked at $8.41M in Q1 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.